The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28039837 |
21 |
Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines. |
Masaryk University |
| 27171036 |
164 |
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. |
University of Nebraska Medical Center |
| 27189674 |
84 |
RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones. |
Beni-Suef University |
| 26851505 |
65 |
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. |
Palack£ |
| 26706349 |
12 |
Synthesis and pharmacological evaluation of dehydroabietic acid thiourea derivatives containing bisphosphonate moiety as an inducer of apoptosis. |
Southeast University |
| 26706352 |
2 |
Bis-isatin hydrazones with novel linkers: Synthesis and biological evaluation as cytotoxic agents. |
Egyptian Russian University |
| 26741853 |
95 |
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors. |
University of Tours |
| 26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). |
Icahn School of Medicine At Mount Sinai |
| 26614408 |
106 |
Identification of azabenzimidazoles as potent JAK1 selective inhibitors. |
Astrazeneca |
| 25914804 |
20 |
Discovery of novel 5-fluoro-N(2),N(4)-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9. |
Chinese Academy of Medical Sciences and Peking Union Medical College |
| 24973661 |
10 |
9- and 11-substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma. |
Technische Universit£T Braunschweig |
| 24793884 |
151 |
Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. |
Amgen |
| 24681986 |
42 |
Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines. |
Siedlce University of Natural Sciences and Humanities |
| 24417566 |
43 |
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). |
Icahn School of Medicine At Mount Sinai |
| 24120542 |
90 |
The optimization of aminooxadiazoles as orally active inhibitors of Cdc7. |
Amgen |
| 24900442 |
51 |
Discovery of a Novel Series of CHK1 Kinase Inhibitors with a Distinctive Hinge Binding Mode. |
TBA |
| 20153204 |
109 |
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. |
Nerviano Medical Sciences |
| 16476733 |
18 |
Inhibition of S/G2 phase CDK4 reduces mitotic fidelity. |
University of Queensland |
| 22154349 |
123 |
5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors. |
Nerviano Medical Sciences |
| 22014550 |
337 |
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). |
Ansaris |
| 22014755 |
36 |
Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells. |
Hanyang University |
| 21080703 |
20 |
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. |
Imperial College |
| 21561767 |
48 |
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. |
Ariad Pharmaceuticals |
| 21493067 |
22 |
In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. |
Astrazeneca R&D Boston |
| 21470862 |
110 |
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. |
Nerviano Medical Sciences |
| 21417417 |
8 |
Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity. |
Palacky£? University and Institute of Experimental Botany Ascr |
| 20472447 |
45 |
Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK). |
Nycomed Pharma |
| 20462263 |
127 |
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. |
Cyclacel |
| 20397705 |
208 |
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors. |
Nerviano Medical Sciences |
| 20361800 |
22 |
5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. |
Institute of Science and Technology |
| 20141146 |
234 |
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors. |
Nerviano Medical Sciences |
| 15482916 |
64 |
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. |
Pfizer |
| 30639897 |
48 |
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. |
The First Affiliated Hospital of Zhengzhou University |
| 32150405 |
75 |
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? |
Lebanese American University |
| 31477350 |
80 |
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). |
Eli Lilly |
| 31514062 |
80 |
Recent advances in the development of cyclin-dependent kinase 7 inhibitors. |
Tianjin University of Science and Technology |
| 31098000 |
63 |
Discovery of CDK5 Inhibitors through Structure-Guided Approach. |
University of South Australia |
| 31307887 |
64 |
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma. |
Genentech |
| 30943029 |
59 |
3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models. |
Palack£ |
| 31693351 |
473 |
Discovery of 4 |
TBA |
| 30733087 |
53 |
A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs. |
China Pharmaceutical University |
| 31238183 |
13 |
Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity. |
China Pharmaceutical University |
| 30543440 |
86 |
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
University of South Australia Cancer Research Institute |
| 30826188 |
25 |
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances. |
University of Science & Technology (Ust) |
| 30384048 |
365 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. |
University of Florida |
| 30343954 |
16 |
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. |
Eppley Institute For Research In Cancer and Allied Diseases |
| 31895562 |
76 |
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2- |
Takeda Pharmaceutical |
| 31710489 |
55 |
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC). |
Astrazeneca |
| 31629164 |
82 |
3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights. |
Egyptian Russian University |
| 30234987 |
232 |
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? |
Palack£ |
| 25908517 |
14 |
Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9. |
Chinese Academy of Medical Sciences and Peking Union Medical College |
| 25835357 |
22 |
Novel arylazopyrazole inhibitors of cyclin-dependent kinases. |
Palack� |
| 25368960 |
17 |
Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a nonplanar analogue of fascaplysin, inhibits Cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity. |
De Montfort University |
| 31200237 |
95 |
Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer. |
Shanghai Pharmaceuticals Holding |
| 22819191 |
17 |
Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents. |
Changzhou University |
| 19889545 |
34 |
Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2. |
Daiichi Sankyo |
| 29046238 |
17 |
1,3,5-Triazines: A promising scaffold for anticancer drugs development. |
Universit£ |
| 28135685 |
91 |
ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles. |
Palack£ |
| 29247857 |
102 |
A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. |
Beijing Normal University |
| 29273417 |
26 |
An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold. |
University of Kwazulu-Natal |
| 29089259 |
50 |
Trisubstituted purine inhibitors of PDGFR? and their antileukemic activity in the human eosinophilic cell line EOL-1. |
Palack£ |
| 28284870 |
77 |
Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones. |
Takeda Pharmaceutical |
| 29853338 |
31 |
Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells. |
Shihezi University |
| 28533114 |
91 |
2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase. |
Takeda Pharmaceutical |
| 28557430 |
45 |
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule. |
University of Kaiserslautern |
| 16242653 |
33 |
A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression. |
Gpc Biotech |
| 19603809 |
59 |
Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor. |
Nerviano Medical Sciences |
| 17697781 |
29 |
Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors. |
Amgen |
| 17064073 |
78 |
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. |
Hoffmann-La Roche |
| 16290148 |
44 |
3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors. |
Nerviano Medical Sciences |
| 17064068 |
36 |
4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. |
Palacky University |
| 11170642 |
12 |
Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. |
Lawrence Berkeley National Laboratory |
| 15985434 |
18 |
Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. |
Chinese Academy of Sciences |
| 10891109 |
19 |
Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. |
Palacky University |
| 12852944 |
26 |
3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors. |
Hoffmann-La Roche |
| 15012993 |
22 |
A new series of potent oxindole inhibitors of CDK2. |
Hoffmann-La Roche |
| 12659774 |
20 |
Synthesis of potent oxindole CDK2 inhibitors. |
Hoffmann-La Roche |
| 15261277 |
30 |
Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. |
Cyclacel |
| 15027857 |
66 |
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. |
Cyclacel |
| 15081018 |
14 |
Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. |
Astrazeneca |
| 15081017 |
17 |
Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. |
Astrazeneca |
| 12941325 |
18 |
Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation. |
Astrazeneca |
| 12941312 |
58 |
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines. |
Astrazeneca |
| 12941311 |
34 |
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines. |
Astrazeneca |
| 15664865 |
37 |
Novel CDK inhibition profiles of structurally varied 1-aza-9-oxafluorenes. |
Martin-Luther-University Halle-Wittenberg |
| 12749903 |
69 |
Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors. |
Sugen |
| 15189033 |
48 |
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. |
Pharmacia Italia |
| 11311054 |
14 |
Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors. |
Dupont Pharmaceuticals |
| 11354366 |
81 |
Quinazolines as cyclin dependent kinase inhibitors. |
Dupont Pharmaceuticals |
| 15482910 |
53 |
Parallel synthesis of acylsemicarbazide libraries: preparation of potent cyclin dependent kinase (cdk) inhibitors. |
Dupont Pharmaceuticals |
| 12747775 |
56 |
Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. |
Eli Lilly |
| 12824014 |
284 |
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. |
Eli Lilly |
| 14552792 |
53 |
Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides. |
Eli Lilly |
| 15149644 |
37 |
Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors. |
Eli Lilly |
| 15149678 |
32 |
1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors. |
Eli Lilly |
| 15225699 |
27 |
Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors. |
Eli Lilly |
| 15546737 |
59 |
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation. |
Avenida De La Industria |
| 15780638 |
45 |
Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases. |
Eli Lilly |
| 15801830 |
127 |
Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. |
Pfizer |
| 15993068 |
101 |
2-Aminoquinazoline inhibitors of cyclin-dependent kinases. |
Naeja Pharmaceutical |
| 11101352 |
88 |
Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. |
Parke-Davis Pharmaceutical Research |
| 14698155 |
68 |
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3. |
Bristol-Myers Squibb |
| 15537345 |
171 |
Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases. |
Bristol-Myers Squibb |
| 15027863 |
17 |
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. |
Bristol-Myers Squibb |
| 12643928 |
24 |
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases. |
Bristol-Myers Squibb |
| 12824044 |
41 |
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues. |
Bristol-Myers Squibb |
| 12431050 |
76 |
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern. |
Bristol-Myers Squibb |
| 15125971 |
24 |
Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases. |
Bristol-Myers Squibb |
| 11063609 |
36 |
Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 12190313 |
94 |
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 12431051 |
114 |
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2). |
Bristol-Myers Squibb |
Search and Browse
